切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 237 -240. doi: 10.3877/cma.j.issn.1674-3946.2020.03.008

所属专题: 文献

论著

联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌的近期随访
朱学河1, 马丽杰2, 吴魏1,()   
  1. 1. 010050 内蒙古医科大学附属医院
    2. 010050 内蒙古医科大学
  • 收稿日期:2019-12-31 出版日期:2020-06-26
  • 通信作者: 吴魏

Short-term follow-up of combined lobectomy with arterial resection and reconstruction for hilar cholangiocarcinoma

Xuehe Zhu1, Lijie Ma2, Wei Wu1,()   

  1. 1. Affiliated Hospital of Inner Mongolia Medical University 010050
    2. Inner Mongolia Medical University 010050
  • Received:2019-12-31 Published:2020-06-26
  • Corresponding author: Wei Wu
  • About author:
    Corresponding author: Wu Wei, Email:
  • Supported by:
    National Natural Science Foundation of China(2016MS08134)
引用本文:

朱学河, 马丽杰, 吴魏. 联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌的近期随访[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(03): 237-240.

Xuehe Zhu, Lijie Ma, Wei Wu. Short-term follow-up of combined lobectomy with arterial resection and reconstruction for hilar cholangiocarcinoma[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(03): 237-240.

目的

探讨联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌(HCCA)的临床效果和预后情况。

方法

回顾性分析2016年10月至2019年10月肝动脉受侵HCCA患者98例资料,根据手术方式不同将患者分为联合组(HCCA根治术+肝叶切除+肝动脉切除重建术)51例和姑息组(姑息性胆管肿瘤切除术/内引流减黄手术)47例。所有数据均采用SPSS22.0软件处理分析,两组患者术中术后各项指标以(±s)表示,采用独立样本t检验。并发症比较采用χ2检验;采用Kaplanmeier绘制患者的生存曲线;以P<0.05为差异有统计学意义。

结果

联合组手术时间、住院费用明显高于姑息组,但术中出血量、住院时间明显低于姑息组(P<0.05)。联合组并发症发生率为52.9%,与姑息组的42.6%比较,差异无统计学意义(P>0.05);两组均未发生围术期死亡。随访时间截至2019年11月,联合组的1年、2年、3年生存率分别为84.3%、66.7%、43.1%,,明显高于姑息组的17.0%、10.6%、4.3%(P<0.05)。

结论

联合肝叶及血管切除重建根治术用于治疗肝动脉受侵HCCA,可有效减少术中出血量,提高患者的生存率。

Objective

To investigate the clinical effect and prognosis of combined lobectomy with arterial resection and reconstruction for patients of hepatic artery invasion of hilar cholangiocarcinoma(HCCA).

Methods

98 cases of HCCA with hepatic artery invasion from October 2016 to October 2019 were retrospectively analyzed. According to different surgical methods, the patients were divided into combined group (HCCA radical surgery + lobectomy + hepatic artery resection, 51 cases) and palliative group (palliative bile duct tumor resection / internal drainage reduction surgery, 47 cases). All the data were analyzed by spss22.0 software. The indexes of the patients in the two groups were expressed by (±s), and independent sample t test was used to compare. The complications were compared by χ2 test, Kaplan-Meier was used to plot the survival curve of patients, and P<0.05 was considered statistically significant.

Results

The operation time and hospitalization cost in the combined group were significantly higher than those in the palliative group. The intraoperative blood loss and hospital stay in the combined group were significantly lower than those in the palliative group, and the differences were statistically significant (P<0.05). The complication rate in the combined group was 52.9%, compared with 42.5% in the palliative group, the difference was not statistically significant (P>0.05); no perioperative death occurred in both groups. The follow-up time was up to November 2019. After 1 to 36 months of follow-up, all patients in the combined group had a one-year survival rate, a two-year survival rate, and a three-year survival rate of 84.3%, 66.7%, and 43.1%, which were significantly higher than 17.0%, 10.6%, 4.3% in the palliative group, the differences were statistically significant (P<0.05).

Conclusion

The combined lobectomy with arterial resection and reconstruction can effectively reduce the amount of bleeding and improve the survival rate of patients with HCCA.

表1 98例肝动脉受侵HCCA患者不同术式两组一般资料比较[(±s),例]
表2 98例肝动脉受侵HCCA患者不同术式两组术中术后各项指标比较(±s)
表3 98例肝动脉受侵HCCA患者不同术式两组并发症发生率比较(例)
图1 98例肝动脉受侵HCCA患者不同术式两组患者术后生存曲线
表4 98例肝动脉受侵HCCA患者不同术式两组生存率比较 [例(%)]
[1]
胡海洁,靳艳文,林圯昕,等.肝门部胆管癌肿瘤直径及相关预后指标对患者预后的影响因素分析[J].中华消化外科杂志,2018,17(3):266-272.
[2]
戴伟,钱叶本.Bismuth-CorletteⅢ型肝门部胆管癌治疗策略[J].中华普通外科杂志,2019,34(1):14-17.
[3]
李敏,宋洁琼,宋陆军,等.术前吲哚菁绿清除试验预测肝门部胆管癌患者肝储备功能[J].中华肝胆外科杂志,2019,25(8):565-569.
[4]
倪传斗,宋春峰,杨明军,等.肝门部胆管癌的术前评估和外科治疗现状[J].国际肿瘤学杂志,2018,45(11):692-695.
[5]
陈明.66例肝门胆管癌合并阻塞性黄疸病例介入治疗的回顾性分析[J/CD].中华普外科手术学杂志(电子版),2019,13(5):501-503.
[6]
徐霖,俞文隆,于观贞,等.ALDH1A1和ALDH6A1在肝门部胆管癌中的表达及其临床意义[J].临床肿瘤学杂志,2017,22(11):990-995.
[7]
张登勇,孙万亮,马翔,等.肝门胆管癌70例临床诊治分析[J].中华医学杂志,2019,99(4):284-287.
[8]
Loveday BPT, Knox JJ, Dawson LA,et al.Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada[J].J Surg Oncol,2018,117(2):213-219.
[9]
徐后云,余细平,冯锐,等.肝癌患者肝动脉化疗栓塞术后相关性胆管损伤与血管栓塞位置的关系及临床预后分析[J].中华肿瘤杂志,2017,39(5):355-360.
[10]
戴海粟,别平,王曙光,等.联合肝动脉切除重建在肝门部胆管癌根治术中的临床研究[J].中华外科杂志,2018,56(1):41-46.
[11]
Malik A, Robinson S, French J,et al.Chemotherapy for hilar cholangiocarcinoma (HCCA): Outcomes in a tertiary referral centre[J].European Journal of Surgical Oncology,2018,44(11):S16.
[12]
Malik AK, Robinson SM, French JJ,et al.Surgery for Hilar cholangiocarcinoma: the Newcastle upon Tyne Liver Unit experience[J].European Surgery,2019,51(4):197-205.
[13]
金望迅,王兵,黄灵,等.影响二步肝切除术肝脏再生的主要因素研究[J].中华全科医学,2019,17(6):927-931,1032.
[14]
朱飞鹏,季顾惟,刘希胜,等.多排螺旋CT评估肝门部胆管癌胆道侵犯的准确性[J].中国临床研究,2017,30(12):1593-1596.
[15]
陈琳,陈孝平.肝门部胆管癌个体化治疗的现状与思考[J].国际外科学杂志,2018,45(6):361-363.
[16]
杨建明,杨丹丹,张伟浩,等.肝门部胆管癌术后常见并发症的预防与处理[J].腹部外科,2019,32(1):68-71.
[17]
刘百铭,苏洋.肝门部胆管癌手术治疗争议点的研究现状[J].中国医师进修杂志,2019,42(5):467-470.
[18]
田立斌,张海光,鲁鑫,等.淋巴增强因子1及细胞周期蛋白D1在肝门部胆管癌中的表达及其临床意义[J].临床与病理杂志,2018,38(5):942-946.
[19]
Aloia TA.Precision Hilar Cholangiocarcinoma Surgery[J].Ann Surg Oncol,2018,25(5):1103-1104.
[20]
Poruk KE, Pawlik TM, Weiss MJ.Perioperative Management of Hilar Cholangiocarcinoma[J].J Gastrointest Surg,2015,19(10):1889-1899.
[21]
Mansour JC, Aloia TA, Crane CH,et al.Hilar cholangiocarcinoma: expert consensus statement[J].HPB(Oxford),2015,17(8):691-699.
[1] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[5] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[6] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[7] 郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[8] 魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
[9] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[11] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[12] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[13] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[14] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?